Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 465

1.

Comprehensive T cell repertoire characterization of non-small cell lung cancer.

Reuben A, Zhang J, Chiou SH, Gittelman RM, Li J, Lee WC, Fujimoto J, Behrens C, Liu X, Wang F, Quek K, Wang C, Kheradmand F, Chen R, Chow CW, Lin H, Bernatchez C, Jalali A, Hu X, Wu CJ, Eterovic AK, Parra ER, Yusko E, Emerson R, Benzeno S, Vignali M, Wu X, Ye Y, Little LD, Gumbs C, Mao X, Song X, Tippen S, Thornton RL, Cascone T, Snyder A, Wargo JA, Herbst R, Swisher S, Kadara H, Moran C, Kalhor N, Zhang J, Scheet P, Vaporciyan AA, Sepesi B, Gibbons DL, Robins H, Hwu P, Heymach JV, Sharma P, Allison JP, Baladandayuthapani V, Lee JJ, Davis MM, Wistuba II, Futreal PA, Zhang J.

Nat Commun. 2020 Jan 30;11(1):603. doi: 10.1038/s41467-019-14273-0.

2.

PI4KIIIβ is a therapeutic target in chromosome 1q-amplified lung adenocarcinoma.

Tan X, Banerjee P, Pham EA, Rutaganira FUN, Basu K, Bota-Rabassedas N, Guo HF, Grzeskowiak CL, Liu X, Yu J, Shi L, Peng DH, Rodriguez BL, Zhang J, Zheng V, Duose DY, Solis LM, Mino B, Raso MG, Behrens C, Wistuba II, Scott KL, Smith M, Nguyen K, Lam G, Choong I, Mazumdar A, Hill JL, Gibbons DL, Brown PH, Russell WK, Shokat K, Creighton CJ, Glenn JS, Kurie JM.

Sci Transl Med. 2020 Jan 22;12(527). pii: eaax3772. doi: 10.1126/scitranslmed.aax3772.

PMID:
31969487
3.

Computational staining of pathology images to study the tumor microenvironment in lung cancer.

Wang S, Rong R, Yang DM, Fujimoto J, Yan S, Cai L, Yang L, Luo D, Behrens C, Parra ER, Yao B, Xu L, Wang T, Zhan X, Wistuba II, Minna J, Xie Y, Xiao G.

Cancer Res. 2020 Jan 8. pii: canres.1629.2019. doi: 10.1158/0008-5472.CAN-19-1629. [Epub ahead of print]

PMID:
31915129
4.

Multifactorial deep learning reveals pan-cancer genomic tumor clusters with distinct immunogenomic landscape and response to immunotherapy.

Xie F, Zhang J, Wang J, Reuben A, Xu W, Yi X, Varn FS, Ye Y, Cheng J, Yu M, Wang Y, Liu Y, Xie M, Du P, Ma K, Ma X, Zhou P, Yang S, Chen Y, Wang G, Xia X, Liao Z, Heymach JV, Wistuba II, Futreal PA, Ye K, Cheng C, Xia T.

Clin Cancer Res. 2020 Jan 7. pii: clincanres.1744.2019. doi: 10.1158/1078-0432.CCR-19-1744. [Epub ahead of print]

PMID:
31911545
5.

Achieving Complete Remission in CLL Patients Treated with Ibrutinib: Clinical Significance and Predictive Factors.

Strati P, Schlette EJ, Solis Soto L, Dueñas-Hancco DE, Sivina M, Kim E, Keating M, Wierda WG, Ferrajoli A, Kantarjian H, Estrov Z, Jain N, Thompson PA, Wistuba II, Burger JA.

Blood. 2020 Jan 2. pii: blood.2019003570. doi: 10.1182/blood.2019003570. [Epub ahead of print] No abstract available.

PMID:
31895947
6.

RUVBL1/RUVBL2 ATPase Activity Drives PAQosome Maturation, DNA Replication and Radioresistance in Lung Cancer.

Yenerall P, Das AK, Wang S, Kollipara RK, Li LS, Villalobos P, Flaming J, Lin YF, Huffman K, Timmons BC, Gilbreath C, Sonavane R, Kinch LN, Rodriguez-Canales J, Moran C, Behrens C, Hirasawa M, Takata T, Murakami R, Iwanaga K, Chen BPC, Grishin NV, Raj GV, Wistuba II, Minna JD, Kittler R.

Cell Chem Biol. 2020 Jan 16;27(1):105-121.e14. doi: 10.1016/j.chembiol.2019.12.005. Epub 2019 Dec 26.

PMID:
31883965
7.

Round Robin Evaluation of MET Protein Expression in Lung Adenocarcinomas Improves Interobserver Concordance.

Boyle TA, Khalil FK, Mino-Kenudson M, Sica GL, Moreira AL, Sholl LM, Knight MZ, Zhang L, Saller J, Varella-Garcia M, Berry LD, Chen H, Ellison KE, Rivard CJ, Kugler K, Wistuba II, Fujimoto J, Kwiatkowski DJ, Bunn PA, Kris MG, Haura EB, Hirsch FR; Lung Cancer Mutation Consortium (LCMC) Pathologist Panel Group.

Appl Immunohistochem Mol Morphol. 2019 Nov 22. doi: 10.1097/PAI.0000000000000810. [Epub ahead of print]

PMID:
31876606
8.

PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee.

Lantuejoul S, Sound-Tsao M, Cooper WA, Girard N, Hirsch FR, Roden AC, Lopez-Rios F, Jain D, Chou TY, Motoi N, Kerr KM, Yatabe Y, Brambilla E, Longshore J, Papotti M, Sholl LM, Thunnissen E, Rekhtman N, Borczuk A, Bubendorf L, Minami Y, Beasley MB, Botling J, Chen G, Chung JH, Dacic S, Hwang D, Lin D, Moreira A, Nicholson AG, Noguchi M, Pelosi G, Poleri C, Travis W, Yoshida A, Daigneault JB, Wistuba II, Mino-Kenudson M.

J Thorac Oncol. 2019 Dec 20. pii: S1556-0864(19)33847-X. doi: 10.1016/j.jtho.2019.12.107. [Epub ahead of print] Review.

PMID:
31870882
9.

High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer.

Massarelli E, Lam VK, Parra ER, Rodriguez-Canales J, Behrens C, Diao L, Wang J, Blando J, Byers LA, Yanamandra N, Brett S, Morley P, Sharma P, Allison J, Wistuba II, Heymach JV.

J Immunother Cancer. 2019 Dec 16;7(1):351. doi: 10.1186/s40425-019-0827-2.

10.

Correction: Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation.

Jin Y, Bao H, Le X, Fan X, Tang M, Shi X, Zhao J, Yan J, Xu Y, Quek K, Elamin YY, Zhang J, Futreal PA, Wistuba II, Heymach JV, Lou G, Shao L, He Q, Lin C, Wu X, Shao YW, Wang X, He J, Chen Y, Stebbing J, Chen M, Zhang J, Yu X.

Oncogene. 2019 Dec 12. doi: 10.1038/s41388-019-1143-5. [Epub ahead of print]

PMID:
31831835
11.

From clinical specimens to human cancer preclinical models-a journey the NCI-cell line database-25 years later.

Mulshine JL, Ujhazy P, Antman M, Burgess CM, Kuzmin I, Bunn PA Jr, Johnson BE, Roth JA, Pass HI, Ross SM, Aldige CR, Wistuba II, Minna JD.

J Cell Biochem. 2019 Dec 5. doi: 10.1002/jcb.29564. [Epub ahead of print]

PMID:
31803961
12.

Immunotherapy response evaluation with magnetic resonance elastography (MRE) in advanced HCC.

Qayyum A, Hwang KP, Stafford J, Verma A, Maru DM, Sandesh S, Sun J, Pestana RC, Avritscher R, Hassan MM, Amin H, Rashid A, Wistuba II, Ehman RL, Ma J, Kaseb AO.

J Immunother Cancer. 2019 Nov 28;7(1):329. doi: 10.1186/s40425-019-0766-y.

13.

ConvPath: A software tool for lung adenocarcinoma digital pathological image analysis aided by a convolutional neural network.

Wang S, Wang T, Yang L, Yang DM, Fujimoto J, Yi F, Luo X, Yang Y, Yao B, Lin S, Moran C, Kalhor N, Weissferdt A, Minna J, Xie Y, Wistuba II, Mao Y, Xiao G.

EBioMedicine. 2019 Dec;50:103-110. doi: 10.1016/j.ebiom.2019.10.033. Epub 2019 Nov 22.

14.

Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation.

Jin Y, Bao H, Le X, Fan X, Tang M, Shi X, Zhao J, Yan J, Xu Y, Quek K, Elamin YY, Zhang J, Futreal PA, Wistuba II, Heymach JV, Lou G, Shao L, He Q, Lin C, Wu X, Shao YW, Wang X, He J, Chen Y, Stebbing J, Chen M, Zhang J, Yu X.

Oncogene. 2019 Nov 21. doi: 10.1038/s41388-019-1104-z. [Epub ahead of print] Erratum in: Oncogene. 2019 Dec 12;:.

PMID:
31754213
15.

The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma.

Zhuo M, Guan Y, Yang X, Hong L, Wang Y, Li Z, Chen R, Abbas H, Chang L, Gong Y, Wu N, Zhong J, Chen W, Chen H, Dong Z, Zhu X, Li J, Wang Y, An T, Wu M, Wang Z, Wang J, Roarty EB, Rinsurongkawong W, Lewis J, Roth JA, Swisher SG, Lee JJ, Heymach JV, Wistuba II, Kalhor N, Yang L, Yi X, Futreal PA, Glisson BS, Xia X, Zhang J, Zhao J.

Clin Cancer Res. 2020 Feb 15;26(4):892-901. doi: 10.1158/1078-0432.CCR-19-0556. Epub 2019 Nov 6.

PMID:
31694833
16.

Expression of Epithelial-Mesenchymal Transition Markers in Treated Pancreatic Ductal Adenocarcinoma.

Wang M, Estrella JS, Katz MH, Kim M, Rashid A, Lee JE, Maitra A, Wistuba II, Wolff RA, Varadhachary GR, Wang H.

Pancreas. 2019 Nov/Dec;48(10):1367-1372. doi: 10.1097/MPA.0000000000001432.

PMID:
31688603
17.

Artificial Intelligence in Lung Cancer Pathology Image Analysis.

Wang S, Yang DM, Rong R, Zhan X, Fujimoto J, Liu H, Minna J, Wistuba II, Xie Y, Xiao G.

Cancers (Basel). 2019 Oct 28;11(11). pii: E1673. doi: 10.3390/cancers11111673. Review.

18.

Therapeutic targeting of the PI4K2A/PKR lysosome network is critical for misfolded protein clearance and survival in cancer cells.

Pataer A, Ozpolat B, Shao R, Cashman NR, Plotkin SS, Samuel CE, Lin SH, Kabil NN, Wang J, Majidi M, Fang B, Roth JA, Vaporciyan AA, Wistuba II, Hung MC, Swisher SG.

Oncogene. 2020 Jan;39(4):801-813. doi: 10.1038/s41388-019-1010-4. Epub 2019 Sep 25.

19.

Lymphovascular Invasion Is Associated With Mutational Burden and PD-L1 in Resected Lung Cancer.

Mitchell KG, Negrao MV, Parra ER, Li J, Zhang J, Dejima H, Vaporciyan AA, Swisher SG, Weissferdt A, Antonoff MB, Cascone T, Roarty E, Wistuba II, Heymach JV, Gibbons DL, Zhang J, Sepesi B.

Ann Thorac Surg. 2020 Feb;109(2):358-366. doi: 10.1016/j.athoracsur.2019.08.029. Epub 2019 Sep 21.

PMID:
31550464
20.

Multiplex Immunofluorescence Assays.

Francisco-Cruz A, Parra ER, Tetzlaff MT, Wistuba II.

Methods Mol Biol. 2020;2055:467-495. doi: 10.1007/978-1-4939-9773-2_22.

PMID:
31502166
21.

Non-invasive genotyping of metastatic colorectal cancer using circulating cell free DNA.

Shi X, Duose DY, Mehrotra M, Harmon MA, Hu P, Wistuba II, Kopetz S, Luthra R.

Cancer Genet. 2019 Sep;237:82-89. doi: 10.1016/j.cancergen.2019.06.004. Epub 2019 Jun 12.

PMID:
31447070
22.

Development and Application of Duplex Sequencing Strategy for Cell-Free DNA-Based Longitudinal Monitoring of Stage IV Colorectal Cancer.

Mallampati S, Zalles S, Duose DY, Hu PC, Medeiros LJ, Wistuba II, Kopetz S, Luthra R.

J Mol Diagn. 2019 Nov;21(6):994-1009. doi: 10.1016/j.jmoldx.2019.06.008. Epub 2019 Aug 8.

PMID:
31401123
23.

Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905).

Tsao AS, Miao J, Wistuba II, Vogelzang NJ, Heymach JV, Fossella FV, Lu C, Velasco MR, Box-Noriega B, Hueftle JG, Gadgeel S, Redman MW, Gandara DR, Kelly K.

J Clin Oncol. 2019 Oct 1;37(28):2537-2547. doi: 10.1200/JCO.19.00269. Epub 2019 Aug 6.

24.

A proposal for pathologic processing of breast implant capsules in patients with suspected breast implant anaplastic large cell lymphoma.

Lyapichev KA, Piña-Oviedo S, Medeiros LJ, Evans MG, Liu H, Miranda AR, Hunt KK, Clemens MW, Stewart JM, Amin MB, Quesada AE, Chai SM, Di Napoli A, Yoga A, Dave SK, Wistuba II, Wu Y, Bueso-Ramos CE, Schlette EJ, Ferrufino-Schmidt MC, Loghavi S, Khoury JD, Young KH, Miranda RN.

Mod Pathol. 2019 Aug 5. doi: 10.1038/s41379-019-0337-2. [Epub ahead of print]

PMID:
31383966
25.

Pleural Fluid Cytokine Levels at Baseline and Over Time are Associated With Time to IPC Removal: An Exploratory Study.

Grosu HB, Lu W, Ost DE, Vial MR, Hernandez M, Ghosh N, Noor L, Hasan AM, Bashoura L, Faiz S, Balachandran D, Casal R, Eapen G, Shannon V, Sheshadri A, Tang X, Rahman N, Wistuba II.

J Bronchology Interv Pulmonol. 2020 Jan;27(1):4-13. doi: 10.1097/LBR.0000000000000602.

PMID:
31373905
26.

Tyrosine Threonine Kinase Inhibition Eliminates Lung Cancers by Augmenting Apoptosis and Polyploidy.

Zheng L, Chen Z, Kawakami M, Chen Y, Roszik J, Mustachio LM, Kurie JM, Villalobos P, Lu W, Behrens C, Mino B, Solis LM, Silvester J, Thu KL, Cescon DW, Rodriguez-Canales J, Wistuba II, Mak TW, Liu X, Dmitrovsky E.

Mol Cancer Ther. 2019 Oct;18(10):1775-1786. doi: 10.1158/1535-7163.MCT-18-0864. Epub 2019 Jul 29.

PMID:
31358662
27.

Characterization and Comparison of GITR Expression in Solid Tumors.

Vence L, Bucktrout SL, Fernandez Curbelo I, Blando J, Smith BM, Mahne AE, Lin JC, Park T, Pascua E, Sai T, Chaparro-Riggers J, Subudhi SK, Scutti JB, Higa MG, Zhao H, Yadav SS, Maitra A, Wistuba II, Allison JP, Sharma P.

Clin Cancer Res. 2019 Nov 1;25(21):6501-6510. doi: 10.1158/1078-0432.CCR-19-0289. Epub 2019 Jul 29.

PMID:
31358539
28.

Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy.

Lee HH, Wang YN, Xia W, Chen CH, Rau KM, Ye L, Wei Y, Chou CK, Wang SC, Yan M, Tu CY, Hsia TC, Chiang SF, Chao KSC, Wistuba II, Hsu JL, Hortobagyi GN, Hung MC.

Cancer Cell. 2019 Aug 12;36(2):168-178.e4. doi: 10.1016/j.ccell.2019.06.008. Epub 2019 Jul 18.

PMID:
31327656
29.

Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer.

Kudo Y, Haymaker C, Zhang J, Reuben A, Duose DY, Fujimoto J, Roy-Chowdhuri S, Solis Soto LM, Dejima H, Parra ER, Mino B, Abraham R, Ikeda N, Vaporcyan A, Gibbons D, Zhang J, Lang FF, Luthra R, Lee JJ, Moran C, Huse JT, Kadara H, Wistuba II.

Ann Oncol. 2019 Sep 1;30(9):1521-1530. doi: 10.1093/annonc/mdz207.

PMID:
31282941
30.

Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma.

Hu X, Fujimoto J, Ying L, Fukuoka J, Ashizawa K, Sun W, Reuben A, Chow CW, McGranahan N, Chen R, Hu J, Godoy MC, Tabata K, Kuroda K, Shi L, Li J, Behrens C, Parra ER, Little LD, Gumbs C, Mao X, Song X, Tippen S, Thornton RL, Kadara H, Scheet P, Roarty E, Ostrin EJ, Wang X, Carter BW, Antonoff MB, Zhang J, Vaporciyan AA, Pass H, Swisher SG, Heymach JV, Lee JJ, Wistuba II, Hong WK, Futreal PA, Su D, Zhang J.

Nat Commun. 2019 Jul 5;10(1):2978. doi: 10.1038/s41467-019-10877-8.

31.

Sphingosine Kinase 1 Signaling Promotes Metastasis of Triple-Negative Breast Cancer.

Acharya S, Yao J, Li P, Zhang C, Lowery FJ, Zhang Q, Guo H, Qu J, Yang F, Wistuba II, Piwnica-Worms H, Sahin AA, Yu D.

Cancer Res. 2019 Aug 15;79(16):4211-4226. doi: 10.1158/0008-5472.CAN-18-3803. Epub 2019 Jun 25.

32.

Tumor cellular proliferation is associated with enhanced immune checkpoint expression in stage I non-small cell lung cancer.

Mitchell KG, Parra ER, Nelson DB, Zhang J, Wistuba II, Fujimoto J, Roth JA, Antonoff MB; MD Anderson Lung Cancer Immune Microenvironment Working Group.

J Thorac Cardiovasc Surg. 2019 Sep;158(3):911-919.e6. doi: 10.1016/j.jtcvs.2019.04.084. Epub 2019 May 17.

PMID:
31235357
33.

Hybrid oncocytic/chromophobe renal tumors are molecularly distinct from oncocytoma and chromophobe renal cell carcinoma.

Ruiz-Cordero R, Rao P, Li L, Qi Y, Atherton D, Peng B, Singh RR, Kim TB, Kawakami F, Routbort MJ, Alouch N, Chow CB, Tang X, Lu W, Brimo F, Matin SF, Wood CG, Tannir NM, Wistuba II, Chen K, Wang J, Medeiros LJ, Karam JA, Tamboli P, Sircar K.

Mod Pathol. 2019 Nov;32(11):1698-1707. doi: 10.1038/s41379-019-0304-y. Epub 2019 Jun 23.

PMID:
31231128
34.

Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer.

Rimm DL, Han G, Taube JM, Yi ES, Bridge JA, Flieder DB, Homer R, Roden AC, Hirsch FR, Wistuba II, Pusztai L.

Breast Cancer Res. 2019 Jun 13;21(1):72. doi: 10.1186/s13058-019-1156-6.

35.

YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib.

Garmendia I, Pajares MJ, Hermida-Prado F, Ajona D, Bértolo C, Sainz C, Lavín A, Remírez AB, Valencia K, Moreno H, Ferrer I, Behrens C, Cuadrado M, Paz-Ares L, Bustelo XR, Gil-Bazo I, Alameda D, Lecanda F, Calvo A, Felip E, Sánchez-Céspedes M, Wistuba II, Granda-Diaz R, Rodrigo JP, García-Pedrero JM, Pio R, Montuenga LM, Agorreta J.

Am J Respir Crit Care Med. 2019 Oct 1;200(7):888-899. doi: 10.1164/rccm.201807-1292OC.

PMID:
31166114
36.

Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy.

Soundararajan R, Fradette JJ, Konen JM, Moulder S, Zhang X, Gibbons DL, Varadarajan N, Wistuba II, Tripathy D, Bernatchez C, Byers LA, Chang JT, Contreras A, Lim B, Parra ER, Roarty EB, Wang J, Yang F, Barton M, Rosen JM, Mani SA.

Cancers (Basel). 2019 May 24;11(5). pii: E714. doi: 10.3390/cancers11050714. Review.

37.

Development and Validation of a Pathology Image Analysis-based Predictive Model for Lung Adenocarcinoma Prognosis - A Multi-cohort Study.

Luo X, Yin S, Yang L, Fujimoto J, Yang Y, Moran C, Kalhor N, Weissferdt A, Xie Y, Gazdar A, Minna J, Wistuba II, Mao Y, Xiao G.

Sci Rep. 2019 May 3;9(1):6886. doi: 10.1038/s41598-019-42845-z.

38.

An Integrated Next-Generation Sequencing System for Analyzing DNA Mutations, Gene Fusions, and RNA Expression in Lung Cancer.

Haynes BC, Blidner RA, Cardwell RD, Zeigler R, Gokul S, Thibert JR, Chen L, Fujimoto J, Papadimitrakopoulou VA, Wistuba II, Latham GJ.

Transl Oncol. 2019 Jun;12(6):836-845. doi: 10.1016/j.tranon.2019.02.012. Epub 2019 Apr 12.

39.

Genomic landscape of allelic imbalance in premalignant atypical adenomatous hyperplasias of the lung.

Sivakumar S, San Lucas FA, Jakubek YA, McDowell TL, Lang W, Kallsen N, Peyton S, Davies GE, Fukuoka J, Yatabe Y, Zhang J, Futreal PA, Fowler J, Fujimoto J, Ehli EA, Hawk ET, Wistuba II, Kadara H, Scheet P.

EBioMedicine. 2019 Apr;42:296-303. doi: 10.1016/j.ebiom.2019.03.020. Epub 2019 Mar 21.

40.

Driver Mutations in Normal Airway Epithelium Elucidate Spatiotemporal Resolution of Lung Cancer.

Kadara H, Sivakumar S, Jakubek Y, San Lucas FA, Lang W, McDowell T, Weber Z, Behrens C, Davies GE, Kalhor N, Moran C, El-Zein R, Mehran R, Swisher SG, Wang J, Zhang J, Fujimoto J, Fowler J, Heymach JV, Dubinett S, Spira AE, Ehli EA, Wistuba II, Scheet P.

Am J Respir Crit Care Med. 2019 Sep 15;200(6):742-750. doi: 10.1164/rccm.201806-1178OC.

PMID:
30896962
41.

Gene expression profiling of lichenoid dermatitis immune-related adverse event from immune checkpoint inhibitors reveals increased CD14+ and CD16+ monocytes driving an innate immune response.

Curry JL, Reuben A, Szczepaniak-Sloane R, Ning J, Milton DR, Lee CH, Hudgens C, George S, Torres-Cabala C, Johnson D, Subramanya S, Wargo JA, Mudaliar K, Wistuba II, Prieto VG, Diab A, Tetzlaff MT.

J Cutan Pathol. 2019 Sep;46(9):627-636. doi: 10.1111/cup.13454. Epub 2019 Apr 11.

PMID:
30883858
42.

ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism.

Peng DH, Kundu ST, Fradette JJ, Diao L, Tong P, Byers LA, Wang J, Canales JR, Villalobos PA, Mino B, Yang Y, Minelli R, Peoples MD, Bristow CA, Heffernan TP, Carugo A, Wistuba II, Gibbons DL.

Sci Transl Med. 2019 Mar 13;11(483). pii: eaaq1238. doi: 10.1126/scitranslmed.aaq1238.

43.

Rational "Error Elimination" Approach to Evaluating Molecular Barcoded Next-Generation Sequencing Data Identifies Low-Frequency Mutations in Hematologic Malignancies.

Mallampati S, Duose DY, Harmon MA, Mehrotra M, Kanagal-Shamanna R, Zalles S, Wistuba II, Sun X, Luthra R.

J Mol Diagn. 2019 May;21(3):471-482. doi: 10.1016/j.jmoldx.2019.01.008. Epub 2019 Feb 20.

PMID:
30794984
44.

State-of-the-Art of Profiling Immune Contexture in the Era of Multiplexed Staining and Digital Analysis to Study Paraffin Tumor Tissues.

Parra ER, Francisco-Cruz A, Wistuba II.

Cancers (Basel). 2019 Feb 20;11(2). pii: E247. doi: 10.3390/cancers11020247. Review.

45.

PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer.

Negrao MV, Lam VK, Reuben A, Rubin ML, Landry LL, Roarty EB, Rinsurongkawong W, Lewis J, Roth JA, Swisher SG, Gibbons DL, Wistuba II, Papadimitrakopoulou V, Glisson BS, Blumenschein GR Jr, Lee JJ, Heymach JV, Zhang J.

J Thorac Oncol. 2019 Jun;14(6):1021-1031. doi: 10.1016/j.jtho.2019.02.008. Epub 2019 Feb 16.

PMID:
30780001
46.

Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.

Sen T, Rodriguez BL, Chen L, Corte CMD, Morikawa N, Fujimoto J, Cristea S, Nguyen T, Diao L, Li L, Fan Y, Yang Y, Wang J, Glisson BS, Wistuba II, Sage J, Heymach JV, Gibbons DL, Byers LA.

Cancer Discov. 2019 May;9(5):646-661. doi: 10.1158/2159-8290.CD-18-1020. Epub 2019 Feb 18.

PMID:
30777870
47.

Centrifuged supernatants from FNA provide a liquid biopsy option for clinical next-generation sequencing of thyroid nodules.

Ye W, Hannigan B, Zalles S, Mehrotra M, Barkoh BA, Williams MD, Cabanillas ME, Edeiken-Monroe B, Hu P, Duose D, Wistuba II, Medeiros LJ, Stewart J, Luthra R, Roy-Chowdhuri S.

Cancer Cytopathol. 2019 Mar;127(3):146-160. doi: 10.1002/cncy.22098. Epub 2019 Jan 8.

PMID:
30620446
48.

METTL13 Methylation of eEF1A Increases Translational Output to Promote Tumorigenesis.

Liu S, Hausmann S, Carlson SM, Fuentes ME, Francis JW, Pillai R, Lofgren SM, Hulea L, Tandoc K, Lu J, Li A, Nguyen ND, Caporicci M, Kim MP, Maitra A, Wang H, Wistuba II, Porco JA Jr, Bassik MC, Elias JE, Song J, Topisirovic I, Van Rechem C, Mazur PK, Gozani O.

Cell. 2019 Jan 24;176(3):491-504.e21. doi: 10.1016/j.cell.2018.11.038. Epub 2019 Jan 3.

49.

Inhibitor of Differentiation-1 Sustains Mutant KRAS-Driven Progression, Maintenance, and Metastasis of Lung Adenocarcinoma via Regulation of a FOSL1 Network.

Román M, López I, Guruceaga E, Baraibar I, Ecay M, Collantes M, Nadal E, Vallejo A, Cadenas S, Miguel ME, Jang JH, Martin-Uriz PS, Castro-Labrador L, Vilas-Zornoza A, Lara-Astiaso D, Ponz-Sarvise M, Rolfo C, Santos ES, Raez LE, Taverna S, Behrens C, Weder W, Wistuba II, Vicent S, Gil-Bazo I.

Cancer Res. 2019 Feb 1;79(3):625-638. doi: 10.1158/0008-5472.CAN-18-1479. Epub 2018 Dec 18.

50.

5 protein-based signature for resectable lung squamous cell carcinoma improves the prognostic performance of the TNM staging.

Martínez-Terroba E, Behrens C, Agorreta J, Monsó E, Millares L, Felip E, Rosell R, Ramirez JL, Remirez A, Torre W, Gil-Bazo I, Idoate MA, de-Torres JP, Pio R, Wistuba II, Pajares MJ, Montuenga LM.

Thorax. 2019 Apr;74(4):371-379. doi: 10.1136/thoraxjnl-2018-212194. Epub 2018 Nov 24.

PMID:
30472670

Supplemental Content

Loading ...
Support Center